Work Here?
Genesis Therapeutics
Work Here?
AI-driven drug discovery for pharma partners
Genesis Therapeutics
Work Here?
AI-driven drug discovery for pharma partners
Overview
Genesis Therapeutics uses artificial intelligence to speed up drug discovery for the pharmaceutical industry. Its platform combines 3D spatial graph modeling with advanced molecular simulation to generate potential drug candidates and to explore new chemical spaces and protein targets. They operate on a business-to-business model, partnering with biotech and pharma companies and earning upfront payments and milestones from collaborations (for example, a Lilly deal worth up to $670 million). Their goal is to deliver AI-generated drug ideas and validated leads to collaborators, accelerating the path from target to therapeutic candidate.
About Genesis Therapeutics
Industries
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$400.1M
Headquarters
Burlingame, California
Founded
2019
Get referred to Genesis Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Incyte expanded the deal on May 20, 2026, adding at least five targets.
- Genesis secured $120M upfront consideration and recurring research funding for training and inference.
- Sergey Edunov joined December 2, 2025, signaling stronger foundation-model execution and hiring appeal.
What critics are saying
- Incyte owns exclusive commercialization rights, capping Genesis upside if programs succeed.
- Genesis depends on partner data and compute budgets; contract delays stall model improvements quickly.
- If Pearl underperforms against Isomorphic and Recursion, pharma partnerships shift elsewhere by 2027.
What makes Genesis Therapeutics unique
- Genesis Molecular AI's Pearl beat AlphaFold 3 on OpenBind, October 28, 2025.
- Incyte shared proprietary experimental data, strengthening Genesis GEMS training beyond public datasets.
- Founder-led physics-plus-AI stack targets previously undruggable small molecules, not generic screening.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$400.1M
Above
Industry Average
Funded Over
4 Rounds
Andreessen Horowitz
Menlo VenturesBenefits
Competitive salary
Equity
Medical, dental, & vision insurance
401(k) program
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -3%2 year growth
↓ -1%Incyte and Genesis expand molecular AI collaboration to accelerate drug discovery
Can Genesis Molecular AI leap ahead in biotech with Meta's Llama leader now onboard? Genesis Molecular AI hires Meta's Llama leader Sergey Edunov to lead foundation models. Discover how this move strengthens its AI drug discovery platform. Genesis Molecular AI, the foundation model-driven drug design firm formerly known as Genesis Therapeutics, has appointed Sergey Edunov as Senior Vice President of Foundation Models. The executive hire marks a strategic inflection point as the company prepares to scale its GEMS platform and unveil new generative model research at the NeurIPS 2025 conference. Sergey Edunov is best known for his leadership role in developing Meta Platforms' Llama 2 and Llama 3 large language models. He brings over two decades of software engineering and AI research experience, having previously served as Senior Director of AI Research in Meta's generative AI division. His arrival at Genesis Molecular AI signals the firm's ambition to compete at the highest levels of foundation model development applied to molecular design.
Genesis Therapeutics has successfully raised a $52 million A round to advance its AI-focused drug discovery mission. The company employs a novel simulation approach and a cross-disciplinary team to efficiently explore the vast array of potential medicinal molecules.
Earlier this year, Incyte inked a deal with Genesis Therapeutics to use the biotech company's AI platform to develop small molecule medicines.
Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.
There are no jobs for Genesis Therapeutics right now.
Find jobs on Simplify and start your career today
About Genesis Therapeutics
Industries
AI & Machine Learning
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$400.1M
Headquarters
Burlingame, California
Founded
2019
There are no jobs for Genesis Therapeutics right now.
Find jobs on Simplify and start your career today